Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to <scp><i>KCNT1</i></scp> Variants: An Open Label Study
Fluoxetine may be a potential targeted medication in EIMFS caused by KCNT1 GoF variants. Further research is needed to assess its long-term efficacy and safety. ANN NEUROL 2025;98:48-61.
Authors
- Maria Virginia Soldovieri (ORCID: https://orcid.org/0000-0002-3601-9374)
- Chiara Falamesca (ORCID: https://orcid.org/0000-0001-8323-044X)
- Marina Trivisano (ORCID: https://orcid.org/0000-0002-9841-8581)
- Angela De Dominicis (ORCID: https://orcid.org/0000-0002-8526-1511)
- Maurizio Taglialatela (ORCID: https://orcid.org/0000-0002-8202-0560)
- Cinzia Correale (ORCID: https://orcid.org/0000-0002-9302-5412)
- Ilenio Servettini (ORCID: https://orcid.org/0000-0002-6163-7975)
- Nicola Specchio (ORCID: https://orcid.org/0000-0002-8120-0287)
- Paolo Ambrosino (ORCID: https://orcid.org/0000-0002-7761-5551)
- Bianca Maria Goffredo (ORCID: https://orcid.org/0000-0001-9933-3240)
- Ilaria Mosca
- Deborah Puzo
- Licia Salimbene
- Cristina Filosomi
Institutions
- University of Molise (IT)
- University of Sannio (IT)
- Bambino Gesù Children's Hospital (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Naples Federico II (IT)
- KU Leuven (BE)
Publication Details
- Journal
- Annals of Neurology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1002/ana.27213
- Citations
- 3
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- Ministero della Salute